ATRA
Atara Biotherapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$39.83M
P/E Ratio
1.90
EPS
$2.57
Beta
-0.33
52W High
$19.14
52W Low
$3.92
50-Day MA
$5.08
200-Day MA
$10.71
Dividend Yield
—
Profit Margin
27.10%
Forward P/E
232.56
PEG Ratio
0.00
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $120.77M |
| Gross Profit (TTM) | $74.62M |
| EBITDA | $51.59M |
| Operating Margin | -339.60% |
| Return on Equity | -2015.00% |
| Return on Assets | 47.80% |
| Revenue/Share (TTM) | $9.63 |
| Book Value | $-5.26 |
| Price-to-Book | 16.14 |
| Price-to-Sales (TTM) | 0.33 |
| EV/Revenue | 0.354 |
| EV/EBITDA | 1.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -95.10% |
| Shares Outstanding | $8.18M |
| Float | $5.59M |
| % Insiders | 18.33% |
| % Institutions | 45.10% |
Analyst Ratings
Consensus ($9.33 target)
1
Buy2
Hold1
SellData last updated: 4/7/2026